
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9549902/publications.pdf Version: 2024-02-01



1	SAMHD1 in cancer: curse or cure?. Journal of Molecular Medicine, 2022, 100, 351-372.	3.9	15
2	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia, 2022, 36, 885-888.	7.2	38
3	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 2021, 35, 809-822.	7.2	7
4	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 1.	6.2	57
5	Healthâ€related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	2.5	10
6	Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia, 2021, 35, 2602-2615.	7.2	27
7	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 2021, 35, 3007-3011.	7.2	4
8	Lethal systemic and brain infection caused by Prototheca zopfii algae in a patient with acute myeloid leukemia. Medical Mycology Case Reports, 2021, 32, 17-20.	1.3	4
9	î"133p53î± enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity. , 2021, 9, e001846.		6
10	Novel immunotherapies in multiple myeloma – chances and challenges. Haematologica, 2021, 106, 2555-2565.	3.5	21
11	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 2021, 13, 4856.	3.7	3
12	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Advances in Therapy, 2021, 38, 1328-1341.	2.9	2
13	Effect of ABC transporter expression and mutational status on survival rates of cancer patients. Biomedicine and Pharmacotherapy, 2020, 131, 110718.	5.6	21
14	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	17.0	32
15	Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers, 2020, 12, 2322.	3.7	15
16	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 2020, 34, 1853-1865.	7.2	47
17	Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients. Cells, 2020, 9, 299.	4.1	1
18	Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer, 2020, 20, 245.	2.6	7

#	Article	IF	CITATIONS
19	Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. Frontiers in Immunology, 2020, 11, 617699.	4.8	19
20	Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial Journal of Clinical Oncology, 2020, 38, 8508-8508.	1.6	21
21	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 2019, 33, 258-261.	7.2	5
22	Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e43.	0.4	0
23	Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. Blood Cancer Journal, 2019, 9, 13.	6.2	6
24	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 2019, 19, 504.	2.6	25
25	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. Blood Cancer Journal, 2019, 9, 45.	6.2	7
26	Teaming up for CAR-T cell therapy. Haematologica, 2019, 104, 2335-2336.	3.5	7
27	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e208.	0.4	0
28	Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. Frontiers in Oncology, 2019, 9, 1268.	2.8	30
29	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
30	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
31	The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncolmmunology, 2018, 7, e1486356.	4.6	14
32	Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms. Blood, 2018, 132, 3205-3205.	1.4	2
33	Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter PhaseAIII Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e76.	0.4	0
34	Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression. Frontiers in Immunology, 2017, 8, 864.	4.8	50
35	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR) Journal of Clinical Oncology, 2017, 35, 8036-8036.	1.6	4
36	Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites. PLoS Neglected Tropical Diseases, 2017, 11, e0005727.	3.0	13

#	Article	IF	CITATIONS
37	Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. Frontiers in Immunology, 2016, 7, 517.	4.8	39
38	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 2016, 101, e485-e487.	3.5	14
39	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246
40	Induced arginine transport via cationic amino acid transporterâ€1 is necessary for human Tâ€cell proliferation. European Journal of Immunology, 2016, 46, 92-103.	2.9	51
41	Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial. Blood, 2016, 128, 3373-3373.	1.4	2
42	Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production. PLoS Neglected Tropical Diseases, 2016, 10, e0004468.	3.0	28
43	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica, 2015, 100, 964-969.	3.5	62
44	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 4233-4233.	1.4	2
45	Interfering with Arginine Metabolism As a New Treatment Strategy for Multiple Myeloma. Blood, 2015, 126, 3005-3005.	1.4	2
46	Protein energy malnutrition increases arginase activity in monocytes and macrophages. Nutrition and Metabolism, 2014, 11, 51.	3.0	20
47	Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages. Frontiers in Immunology, 2014, 5, 532.	4.8	868
48	Macrophage: SHIP of Immunity. Frontiers in Immunology, 2014, 5, 620.	4.8	54
49	Granulocyte functions are independent of arginine availability. Journal of Leukocyte Biology, 2014, 96, 1047-1053.	3.3	16
50	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial. Blood, 2014, 124, 3475-3475.	1.4	1
51	Characterization of Neutrophil Subsets in Healthy Human Pregnancies. PLoS ONE, 2014, 9, e85696.	2.5	67
52	Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. Blood, 2014, 124, 4777-4777.	1.4	0
53	Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection. PLoS Neglected Tropical Diseases, 2013, 7, e1977.	3.0	48
54	Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia. PLoS Neglected Tropical Diseases, 2013, 7, e2134.	3.0	56

#	Article	IF	CITATIONS
55	Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine Depletion. PLoS ONE, 2013, 8, e63521.	2.5	27
56	GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy. Blood, 2013, 122, 3369-3369.	1.4	3
57	Phenotypic Alteration of Neutrophils in the Blood of HIV Seropositive Patients. PLoS ONE, 2013, 8, e72034.	2.5	54
58	Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial. Blood, 2013, 122, 1897-1897.	1.4	0
59	Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in Ethiopia. PLoS Neglected Tropical Diseases, 2012, 6, e1684.	3.0	52
60	Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. International Immunology, 2012, 24, 303-313.	4.0	54
61	Depletion of <scp>L</scp> -arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes. Autophagy, 2012, 8, 1557-1576.	9.1	68
62	A Role for Toll-Like Receptor Mediated Signals in Neutrophils in the Pathogenesis of the Anti-Phospholipid Syndrome. PLoS ONE, 2012, 7, e42176.	2.5	39
63	Characterization of a Novel Population of Low-Density Granulocytes Associated with Disease Severity in HIV-1 Infection. PLoS ONE, 2012, 7, e48939.	2.5	111
64	Role of arginase in asthma: potential clinical applications. Expert Review of Clinical Pharmacology, 2010, 3, 17-23.	3.1	8
65	Human eosinophil granulocytes do not express the enzyme arginase. Journal of Leukocyte Biology, 2010, 87, 1125-1132.	3.3	13
66	Local Suppression of T Cell Responses by Arginase-Induced L-Arginine Depletion in Nonhealing Leishmaniasis. PLoS Neglected Tropical Diseases, 2009, 3, e480.	3.0	90
67	Monocyte Dependent Regulation of Autoimmune Inflammation. Current Molecular Medicine, 2009, 9, 23-29.	1.3	54
68	Regulation of NK Cell Function by Human Granulocyte Arginase. Journal of Immunology, 2009, 182, 5259-5267.	0.8	106
69	<scp>L</scp> â€Arginine deprivation impairs <i>Leishmania major</i> â€specific Tâ€cell responses. European Journal of Immunology, 2009, 39, 2161-2172.	2.9	63
70	Low Levels of Prothrombin Time (INR) and Platelets Do Not Increase the Risk of Significant Bleeding when Placing Central Venous Catheters*. Medizinische Klinik, 2009, 104, 331-335.	0.3	37
71	Arginase: an emerging key player in the mammalian immune system. British Journal of Pharmacology, 2009, 158, 638-651.	5.4	589
72	Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. Trends in Immunology, 2009, 30, 522-530.	6.8	237

#	Article	IF	CITATIONS
73	Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients Blood, 2009, 114, 3400-3400.	1.4	0
74	Age-Related Alteration of Arginase Activity Impacts on Severity of Leishmaniasis. PLoS Neglected Tropical Diseases, 2008, 2, e235.	3.0	35
75	Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. European Journal of Immunology, 2007, 37, 935-945.	2.9	150
76	GCN2 Kinase: An Evolutionarily Conserved Mechanism of Human T Lymphocyte Suppression Upon Arginine Depletion. Clinical Immunology, 2007, 123, S113.	3.2	0
77	Suppression of T-cell functions by human granulocyte arginase. Blood, 2006, 108, 1627-1634.	1.4	341
78	Highly Efficient Expansion of Human CD4+CD25+ Regulatory T Cells for Cellular Immunotherapy in Patients with Graft-Versus-Host Disease. Journal of Immunotherapy, 2006, 29, 336-349.	2.4	41
79	Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes?. Blood, 2005, 106, 2871-2878.	1.4	27
80	Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood, 2005, 105, 2549-2556.	1.4	283
81	Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial. SSRN Electronic Journal. 0	0.4	2